Phio Pharmaceuticals Corp. announced on January 13, 2025, promising pathologic responses for patients enrolled in the second cohort of its PH-762 Phase 1b clinical study. The ongoing Phase 1b clinical study (NCT 06014086) is designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in various skin cancers, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
Results are now available for four patients who completed treatment in the second cohort. Two patients with cutaneous squamous cell carcinoma achieved a complete response, demonstrating 100% tumor clearance. The company reported no dose-limiting toxicities or clinically relevant treatment-emergent adverse events in patients receiving intratumoral PH-762, indicating the injections have been well tolerated.
Mary Spellman MD, Phio's acting Chief Medical Officer, expressed encouragement by the profound tumor response coupled with reassuring safety data. Robert Bitterman, CEO, highlighted these positive results in the early stages of dose escalation as promising for the company's vision of a cancer-free future using INTASYL technology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.